GlassScriptPhysician profile
Charles D Sonido
NPI 1477042026
$8,080.49
in general payments reported to CMS, 2019-2025
32 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.48 · 2020: $46.32 · 2021: $1,018 · 2022: $2,033 · 2023: $1,119 · 2024: $1,886 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,948.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,297.18 | 2021-2025 | Krystexxa, Tepezza, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,119.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $861.07 | 2021-2025 | Vraylar, Dalvance |
| Boston Scientific Corporation | $752.55 | 2024-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.41 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Novo Nordisk INC | $562.13 | 2022-2025 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $375.13 | 2022-2023 | Krystexxa, Tepezza |
| Esperion Therapeutics, INC. | $356.15 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $290.09 | 2021-2025 | |
| Lilly USA, LLC | $259.53 | 2021-2025 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $248.88 | 2021-2025 | Verquvo, Capvaxive, M-M-R II |
| Glaxosmithkline, LLC. | $199.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $163.15 | 2021-2022 | |
| Pfizer INC. | $154.60 | 2021-2024 | |
| Gilead Sciences, INC. | $105.02 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $94.67 | 2021 | |
| Corcept Therapeutics | $69.43 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $58.18 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $53.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.14 | 2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $47.51 | 2025 | Rexulti |
| Lundbeck LLC | $46.46 | 2025 | Rexulti |
| Allergan, INC. | $46.32 | 2020 | |
| Insmed, INC. | $37.33 | 2022 | |
| Echosens North America, INC. | $32.35 | 2024 | Fibroscan |
| Madrigal Pharmaceuticals | $30.00 | 2025 | Rezdiffra |
| Ani Pharmaceuticals, INC. | $28.15 | 2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $27.66 | 2025 | Ohtuvayre |
| Dexcom, INC. | $27.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.08 | 2022 | |
| Medtronic, INC. | $14.31 | 2025 | Venaseal |
| Vertex Pharmaceuticals Incorporated | $14.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sonido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.